The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA‐1, TIMP‐2 levels in children with neurogenic detrusor overactivity due to myelodysplasia

Aims The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment i...

Full description

Saved in:
Bibliographic Details
Published in:Neurourology and urodynamics 2017-09, Vol.36 (7), p.1896-1902
Main Authors: Top, Tuncay, Sekerci, Cagri Akin, Isbilen‐Basok, Banu, Tanidir, Yiloren, Tinay, Ilker, Isman, Ferruh Kemal, Akbal, Cem, Simsek, Ferruh, Tarcan, Tufan
Format: Article
Language:English
Subjects:
Acetylcholine Release Inhibitors - therapeutic use
Biomarkers
botulinum neurotoxin type A
Botulinum toxin
Botulinum toxin type A
Botulinum Toxins, Type A - therapeutic use
Child
Child, Preschool
Children
Enzyme-linked immunosorbent assay
Female
Growth factors
Humans
Injections, Intramuscular
Male
Matrix metalloproteinase
Metalloproteinase
myelodysplasia
Myelodysplastic syndrome
Myelodysplastic syndromes
Nerve growth factor
Nerve Growth Factor - urine
Neural Tube Defects - complications
Prospective Studies
Statistical analysis
tissue inhibitor of matrix metalloproteinase 2
Tissue inhibitor of metalloproteinase 2
Tissue Inhibitor of Metalloproteinase-2 - urine
transforming growth factor beta 1
Transforming Growth Factor beta1 - urine
Transforming growth factor-b1
Treatment Outcome
Urinary Bladder, Neurogenic - drug therapy
Urinary Bladder, Neurogenic - etiology
Urinary Bladder, Neurogenic - urine
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - etiology
Urinary Bladder, Overactive - urine
Urine
Urodynamics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims The aim of this study was to determine the value of urine nerve growth factor (NGF), transforming growth factor beta 1 (TGF‐Beta‐1), tissue inhibitor of matrix metalloproteinase 2 (TIMP‐2) levels to predict the urodynamic profile before and after botulinum neurotoxin type A (BoNT‐A) treatment in children with myelodysplasia. Methods This prospective study included 15 children with myelodysplasia who underwent intradetrusor BoNT‐A injections due to neurogenic detrusor overactivity (NDOA). Urine samples of each child were collected before and after BoNT‐A injections, specifically at the first and third postoperative months. Urine samples were analyzed with ELISA method and NGF, TGF‐Beta‐1, and TIMP‐2 levels were measured. Urine marker levels and clinical findings were assessed for statistical significance with Wilcoxon Signed Ranks Test and Friedman Test. Results A total of 15 children (5 boys and 10 girls) were assigned as the study group. Mean age of the patients was 7.1 ± 2.5 years (range 2.5‐11). A statistically significantly decline was observed in urinary TGF‐Beta‐1 and NGF levels following BoNT‐A injections, compared to the preoperative levels (P 
ISSN:0733-2467
1520-6777
DOI:10.1002/nau.23207